A Phase / Study of Rulonilimab Plus Chemotherapy Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-09-01

Target enrollment:

Participant gender:

This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.

PHASE2

Shandong New Time Pharmaceutical Co., LTD

Carboplatin
Cisplatin